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ABSTRACT 
Objectives: Our study evaluates the impact of adjuvant treatment with external beam 
radiotherapy (EBRT) combined with vaginal high-dose-rate brachytherapy (HDR BT) on 
health-related quality of life (HRQL) in patients with early-stage endometrioid endometrial 
carcinoma. 
Material and methods: We assessed HRQL of patients based on the EORTC QLQ-C30 
questionnaire, with endometrial cancer specific HRQL module — EORTC QLQ-EN24. From 
March 2019 to April 2020 we enrolled 20 patients with early-stage endometrioid endometrial 
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carcinoma, qualified for adjuvant treatment after hysterectomy. We compared the scores 
measured with the questionnaires at the beginning and at the end of the treatment. 
Results: There was a statistically significant decrease in the mean of global health 
status/quality of life assessed according to the EORTC QLQ-C30 scale, from 62.25 ± 13.12 at 
the beginning of the adjuvant radiotherapy to 55.85 ± 14.68 at the end of the treatment (p = 
0.047). The mean appetite loss score was higher at the onset of the treatment as compared to 
its value after EBRT, 19.9 ± 27.33 vs 11.6 ± 19.52 (p = 0.043). Similarly to the mean 
constipation score, which was 29.85 ± 30.40 vs 11.6 ± 19.52 (p = 0.013). The mean diarrhoea 
symptom scale increased from 16.55 ± 20.16 to 56.75 ± 36.10 (p = 0.001). In the EORTC 
QLQ-EN24 scales, gastrointestinal symptoms scores were higher at the end of the treatment, 
(with the mean of 26.45 ± 22.76) as compared to 14.30 ± 16.52 at the beginning of EBRT (p = 
0.003). 
Conclusions: Patients who receive adjuvant radiotherapy have decreased quality of life 
during the treatment reporting more serious gastrointestinal symptoms. The potential risk of 
treatment-related toxicity should be taken into account during the treatment planning process 
in order to minimize the deterioration of HRQL. 
Key words: health-related quality of life; endometrial carcinoma; endometrioid; radiotherapy 
 
INTRODUCTION 
 Endometrial carcinoma is the fourth most common female carcinoma in Poland, with 
an incidence of 7.3 % of all yearly registered malignant neoplasms in women. It causes 3.9 % 
of cancer deaths in women in Poland [1]. Pathologically, endometrial carcinoma is divided 
into two main histological and clinical subtypes: type I — endometrioid adenocarcinoma, 
which is more common and type II — non-endometroid endometrial carcinoma [2]. 
Clinicopathological prognostic factors are staging, tumour histology, grading, lymphovascular 
space invasion (LVSI), depth of myometrial invasion, age and general condition of patients 
[3, 4]. After surgery, in patients with type I endometrial carcinoma staged I B with risk factors 
and at stage II, radiotherapy is the adjuvant treatment of choice [5–8].   
In numerous studies in oncological patients, the impact of adjuvant treatment on 
quality of life has been examined [9, 10]. In tumors localized in the pelvis, long term 
outcomes of quality of life after adding adjuvant radiotherapy show increase of adverse 
urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years 
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after treatment [9]. It is postulated that adjuvant treatment with vaginal high dose rate 
brachytherapy (HDR BT) provides better long-term health-related quality of life (HRQL) than 
external beam radiation therapy (EBRT) [10].  
The HRQL can be measured using validated questionnaires. In patients with 
endometrial carcinoma, it can be done with the European Organization for Research and 
Treatment of Cancer (EORTC) core quality of life questionnaire (EORTC QLQ-C30) with 
Quality of Life Questionnaire-Endometrial Cancer module (EORTC QLQ-EN24) [11–13]. In 
the EORTC QLQ-C30 questionnaire, response scales ranging from 1 to 4 points for all items 
except for items 29 and 30 with response scales from 1 to 7 points. In the EORTC QLQ-EN24 
module, response scales are used, all ranging from 1 to 4 points [12, 14].  
The EORTC QLQ-C30 questionnaire is composed of both multi-item subscales and 
single-item measures. These include: five functional subscales (physical functioning, role 
functioning, emotional functioning, cognitive functioning, social functioning), a global health 
status/QoL scale, three symptom subscales (fatigue, nausea and vomiting, pain) and six single 
symptom items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial 
difficulties). The EORTC QLQ-EN24 module is composed of 5 multi-item scales, from which 
four are used to assess lymphoedema, urological symptoms, gastrointestinal symptoms and 
body image. In addition, five single items are used to evaluate pain in the back and pelvis, 
tingling/numbness, muscular pain, hair loss, taste change [14]. The changes in HRQL 
parameters in patients with type I endometrial carcinoma is still not well defined. 
The aim of our study was to prospectively assess the impact of adjuvant radiotherapy 
on HRQL in patients with type I endometrial carcinoma staged I–II treated at our institution. 
In this paper, we present preliminary results of our study. 
 
MATERIAL AND METHODS 
From March 2019 to April 2020, we enrolled 20 patients aged from 58 to 85 (mean 
68.15 ± 6.43) years old with endometrioid endometrial carcinoma staged I–II in FIGO 
classification. All patients were after total abdominal hysterectomy (TAH). 
Lymphadenectomy of the pelvis was performed in 11 patients, seven patients had no 
lymphadenectomy, and there was a lack of information about lymph node procedure in 2 
patients. Detailed data are presented in Table 1. The patients were qualified for adjuvant 
radiotherapy. The treatment scheme involved the application of EBRT to postoperative bed in 
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the pelvis and regional lymph nodes of a dose up to 44 Gy, fractionated at 2 Gy daily, five 
fractions a week in each patient. In EBRT, the irradiated area was marked according to the 
Radiation Therapy Oncology Group (RTOG) recommendations for adjuvant radiotherapy of 
endometrial carcinoma at stage I–II. It was not dependent on the number of resected 
histologically negative pelvic lymph nodes.  During EBRT, vaginal HDR BT using vaginal 
stamps was implemented, fractionated at one application of 6 Gy or 7.5 Gy weekly for three 
weeks up to a total dose of 18 Gy or 22.5 Gy. The characteristics of the study group are 
presented in Table 2. 
We assessed HRQL in the study group using the EORTC QLQ-C30 questionnaire [14] 
with endometrial cancer-specific HRQL module - EORTC QLQ-EN24 [12]. In both the 
EORTC QLQ-C30 and EORTC QLQ-EN24 questionnaires, the linear transformation was 
performed to standardize the raw score, so that scores ranged from 0 to 100; a higher score 
represented the higher intensity of symptoms. Baseline questionnaires were completed at the 
beginning of treatment and at the completion of EBRT. We compared scores measured with 
EORTC QLQ-C30 and EORTC QLQ-EN24 at the beginning and at the end of treatment. The 
first questionnaire was performed during the first week of treatment, before the first 
application of VBT, the questionnaire at the end of treatment was performed after the last 
application of VBT, during last three days of EBRT. Written informed consent to participate 
in the study was obtained from all patients. 
All statistical analyses were performed using Statistica 13.1 software (Statsoft, Tulsa, 
OK, US). The Wilcoxon signed-rank test was used to compare HRQL scores at the beginning 
and at the end of treatment. The repeated measures ANOVA was used to compare changes in 
time of EORTC QLQ-C30 scales: global health status/quality of life, appetite loss, 
constipation, diarrhoea and EORTC QLQ-EN24 scales: gastrointestinal symptoms, urological 
symptoms and mean pain in the back and pelvis between subgroups. The „p” values below 
0.05 were considered statistically significant. The study was approved by the Bioethics 
Commission of the Medical University of Lodz No. RNN/98/19/KE. 
 
RESULTS 
 There were no statistically significant differences in scores of the EORTC QLQ-C30 
functioning scales (physical functioning, role functioning, emotional functioning, cognitive 
functioning, social functioning) between the onset of treatment and at the end of EBRT (Tab. 
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3). There was a statistically significant decrease in mean of global health status/quality of life 
assessed in the EORTC QLQ-C30 scale, from 62.25 ± 13.12 at the beginning of adjuvant 
radiotherapy to 55.85 ± 14.68 at the end of treatment (p = 0.047) (Fig. 1).  
In the EORTC QLQ-C30 symptoms scales, statistically significant differences 
between the onset and the end of treatment were found in three scales. Mean appetite loss 
score was higher at the onset of treatment than compared to its value after EBRT, 19.9 ± 
27.33 vs 11.6 ± 19.52 (p = 0.043) (Fig. 2), similarly as the mean constipation score, 29.85 ± 
30.40 vs 11.6 ± 19.52 (p = 0.013) (Fig. 3). Mean diarrhoea symptom scale increased from 
16.55 ± 20.16 to 56.75 ± 36.10 (p = 0.001) (Fig. 4). There was no statistically significant 
difference between groups with lymphadenectomy performed and not performed in EORTC 
QLQ-C30 mean of global health status/quality of life, mean appetite loss scale score, mean 
constipation scale score and mean diarrhoea symptom scale score. Analysis of comorbidities 
also showed no differences between subgroups in those scales (Tab. 6). No statistically 
significant differences were found in other EORTC QLQ-C30 symptoms scales (Tab. 4).  
In EORTC QLQ-EN24 symptoms scales, gastrointestinal symptoms scores were 
higher at the end of treatment, with a mean of 26.45 ± 22.76 than compared to 14.30 ± 16.52 
at the beginning of EBRT (p = 0.003) (Fig. 5). No statistically significant differences were 
observed in mean urological symptoms score and mean pain in the back and pelvis score, 
however, the trend toward higher score was clear. The mean urological symptoms score was 
higher at the end of treatment 35.80 ± 31.50 compared to 25.05 ± 22.48 at the beginning (p = 
0.076) (Fig. 6). The mean pain in the back and pelvis score at the beginning and after EBRT 
combined with HDR BT were 23.20 ± 21.89 and 34.85 ± 25.39 (p = 0.103), however 
subgroup analysis showed differences over time between subgroups with a medical history of 
diabetes mellitus (DM) and with no history of DM. No differences between patients with or 
without the medical history of DM were found in gastrointestinal symptoms scale and mean 
urological symptoms scale. There were no differences between subgroups with or with no 
medical history of hypertension or previously lymphadenectomy performed (Tab. 7). 
Lymphoedema symptom scale, poor body image scale, tingling/numbness scale, hair loss 
scale, taste change scale showed no differences. The exact data of scales from EORTC QLQ-
C30 and EORTC QLQ-EN24 modules are presented in Tables 3, 4, 5, 6, 7. 
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DISCUSSION 
When planning EBRT, doses in organs at risk (OARs) are being calculated and 
approved. Maximal doses to organs and dose-volumetric histograms correlate with the risk of 
acute and late radiation toxicity [15]. Dose constraints, maximal doses in OARs or maximal 
volume of OARs that are irradiated up to particular doses, allow to control toxicity at 
reasonable levels [16]. Even in appropriate planned and carried radiotherapy, symptoms of 
acute and late radiation toxicity can be observed. Our results show that in endometrial 
carcinoma patients after surgery, during adjuvant radiotherapy, changes in the HRQL 
occurred. We found the highest differences in symptoms scales regarding gastrointestinal 
symptoms and diarrhoea. 
The HRQL is measured in many oncological clinical trials comparing the use of 
adjuvant treatment and its escalation [9, 10, 17]. It allows us to better identify potential factors 
that worsen and improve HRQL and to prognose and calculate the impact of treatment on 
HRQL. Appropriate prognosis of changes in the HRQL allows for optimal modification of the 
treatment in an individual patient [9, 10, 17].  
The reports describing the influence the mode of surgery on the HRQL in endometrial 
carcinoma patients are present in the literature.  The authors confirmed that minimally 
invasive surgery (robotic, laparoscopic) not only shortens postoperative period but also results 
in a better quality of life of patients compared to open surgery [18].  
The HRQL was also reported in many trials regarding adjuvant radiotherapy in 
endometrial carcinoma patients. The EORTC QLQ-C30 questionnaire to assess the HRQL 
was used in many well-known trials [10, 17], but the EORTC QLQ-EN24 module for 
endometrial carcinoma patients is a relatively new tool with only a few trials reported recently 
[11, 19]. In the PORTEC-1 trial, comparing the use of EBRT with no adjuvant treatment, 
EBRT was associated with long-term urinary and bowel symptoms and lower physical and 
role-physical functioning [9]. The results of the PORTEC-2 trial showed that vaginal 
brachytherapy alone provides better HRQL then EBRT. In the PORTEC-2 for HRQL 
analysis, like in our study, the EORTC QLQ-C30 questionnaire was used, but no endometrial 
can aimed module was available at that time, so some symptoms scales were used from PR25 
(prostate cancer module) and OV28 (ovarian cancer module) [10]. In the PORTEC-3 trial, 
HRQL was measured with EORTC QLQ-C30 with the cervix carcinoma module with 
chemotherapy and neuropathy subscales of the ovarian carcinoma module. This analysis of 
HRQL in that trial showed, that adjuvant chemotherapy given during and after pelvic 
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radiotherapy relates to higher patient-reported symptoms, as well as with decreased level of 
patient functioning and HRQL compared with radiotherapy alone [17].  
The significance of HRQL decrease during any treatment proposed to patients is 
relevant in clinical practice. In our analysis, despite a small group of patients, the impact of 
combined EBRT and HDR BT on HRQL is clear. What is more, further enrollment to our 
study may allow us to find dosimetric and clinical risk factors linked to decreases HQRL 
during adjuvant treatment. 
 
CONCLUSIONS 
Patients who receive adjuvant radiotherapy have decreased quality of life during 
treatment with higher reported gastrointestinal symptoms. 
The potential risk of treatment-related toxicity should be considered during the 
treatment planning process in order to minimize the deterioration of HRQL. 
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Figure 1. Global health status/Quality of life scale change 
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Figure 2. Change of appetit loss scale in time 
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Figure 3. Change of constipation scale in time 
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Figure 4. Change of diarrhoea scale in time 
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Figure 5. Change of urological symptoms scale in time 
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Figure 6. Change of gastrointestinal symptoms scale in time 
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Table 1. Characteristics of patients in the study group 
No. Age 
[years] 
histology FIGO 
stage 
Grading 
[G] 
LVSI TAH PL — number of 
resected lymph 
nodes 
1 63 Endometrioid II 2 – + 21 
2 68 Endometrioid I B 3 – + 1 
3 69 Endometrioid I B 2 + + 33 
4 76 Endometrioid I B 2 + + – 
5 68 Endometrioid I A 2 + + – 
6 76 Endometrioid I B 2 – + – 
7 71 Endometrioid I B 2 – + 12 
8 67 Endometrioid I B 1 + + – 
9 59 Endometrioid I B 2 + + 13 
10 66 Endometrioid I B 2 + + – 
11 67 Endometrioid II 2 – + 22 
12 62 Endometrioid II 2 + + 18 
13 64 Endometrioid II 2 + + 5 
14 85 Endometrioid II 2 – + 19 
15 62 Endometrioid I B 2 + + 6 
16 58 Endometrioid I A 2 + + – 
17 67 Endometrioid II 1 No data + No data 
18 72 Endometrioid I B 2 + + 10 
19 69 Endometrioid I B 2 No data + No data 
20 77 Endometrioid I B 2 No data + – 
PL — pelvic lymphadenectomy 
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Table 2. Characteristics of the study group 
Age at enrollment [years] 
Median [years] 68.15 ± 6.43 
< 60 years 2 (10%) 
60–70 years 6 (30%) 
> 70 years  12 (60%) 
FIGO 2018 Stage 
FIGO IA 2 (10%) 
FIGO IB 12 (60%) 
FIGO II 6 (30%) 
Histological grade 
Grade 1 2 (10%) 
Grade 2 17 (85%) 
Grade 3 1 (5%) 
WHO performance score 
WHO 0 7 (35%) 
WHO 1 12 (60%) 
WHO 2 1 (5%) 
Lymphadenectomy performed 
Yes 11 (55%) 
No 7 (35%) 
Missing data 2 (10 %) 
Median number of resected lymph nodes 14.55 ± 9.20 
Adjuvant Treatment 
EBRT 44 Gy in 22 fractions 20 (100%) 
Vaginal Brachytherapy 3 × 6 Gy 16 (80%) 
Vaginal Brachytherapy 3 × 7.5 Gy 4 (20%) 
Comorbidity 
Diabetes 6 (30%) 
Hypertension 15 (75%) 
BMI 
< 30 8 (40%) 
> 30 12 (60%) 
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Table 3. Results of QLQ C-30 — functioning scales  
EORTC functioning 
scales 
Start of treatment 
Mean (± SD) 
End of treatment 
Mean (± SD) 
P value 
Global health 
status/quality of life 
62.25 (± 13.12) 55.85 (± 14.68) 0.047 
Physical functioning 69 (± 15.47) 74.55 (± 13.02) 0.136 
Role functioning 79.25 (± 22.08) 77.55(± 14.42) 0.594 
Emotional functioning 68.25 (± 20.29) 73.9 (± 17.07) 0.117 
Cognitive functioning 77.55 (± 18.06) 
 
81.75 (± 20.82) 
 
0.154 
Social functioning 76.75 (± 25.54) 73.25 (± 23.22) 0.423 
 
 
 
Table 4. Results of QLQ C-30 — symptoms scales  
EORTC symptoms 
scales 
Start of treatment 
Mean (± SD) 
End of treatment 
Mean (± SD) 
P value 
Fatigue 40.4 (± 22.72) 38.15 (± 20.65) 0.514 
Nausea and vomiting 14.2 (± 17.29) 12,55 (± 17.85) 0.784 
Pain 22.4 (± 17.22) 28.3 (± 21.70) 0.197 
Dyspnoea 19.95(± 25.17) 13.25 (± 19.88) 0.138 
Insomnia 45.0 (± 37.97) 41.55 (± 28.48) 0.433 
Appetite loss 19.9 (± 27.33) 11.6 (± 19.52) 0.043 
Constipation 29.85 (± 30.40) 11.6 (± 19.52) 0.013 
Diarrhoea 16.55 (± 20.16) 56.75 (± 36.10) 0.001 
Financial difficulties 11.6 (± 19.52) 13.3 (± 22.71) 0.423 
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Table 5. Results of EN-24 — symptoms scales  
EORTC symptoms 
scales 
Start of treatment 
Mean (± SD) 
End of treatment 
Mean (± SD) 
P value 
Lymphoedema 29.95 (± 25.23) 28.20 (± 23.58) 0.529 
Urological symptoms 25.05 (± 22.48) 35.80 (± 31.50) 0.076 
Gastrointestinal 
symptoms 
14.30 (± 16.52) 26.45 (± 22.76) 
 
0.003 
Poor body image 26.35 (± 26.23) 27.3 (± 22.41) 0.753 
Pain in back and pelvis 23.20 (± 21.89) 34.85 (± 25.39) 0.103 
Tingling/numbness 13.2 (± 16.59) 9.9 (± 15.51) 0.463 
Muscular pain 18.2 (± 20.09) 19.85 (± 19.87) 0.917 
Hair loss 11.65 (± 22.40) 16.55 (± 20.16) 0.735 
Taste change 11.65 (± 22.40) 13.25 (± 19.88) 0.944 
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Table 6. EORTC QLQ C-30 — differences between groups 
 
 
 
EORTC QLQ-C30  scales 
Questionnaire timepoints P value  
Start of  
treatment 
Mean (± SD) 
End of 
treatment 
Mean (± SD) 
Changes 
over time 
Difference 
between 
groups 
Difference 
between 
groups over 
time 
Global health status/ quality of life scale 
Lymphadenectomy performed 
Yes (n = 11) 62.27 (± 15.95) 59.82 (± 14.86) 0.039 0.402 0.130 
No  (n = 7) 63.29 (± 9.53) 48,86 (± 14.21) 
Diabetes mellitus 
Yes (n = 6) 65.5 (± 8.24) 58.33 (± 17.55) 0.105 0.483 0.889 
No (n = 14) 60.86 (± 14.78) 54.79 (± 13.87) 
Hypertension 
Yes (n = 15) 60.13 (± 14.52) 55.53 (± 16.35) 0.056 0.430 0.382 
No  (n = 5) 68.6 (± 3.58) 56.8 (± 9.31) 
Appetite Loss symptoms scale 
Lymphadenectomy performed 
Yes (n = 11) 15.09 (± 22.91) 9 (± 15.41)            0.014 0.423 0.290 
No  (n = 7) 28.43 (± 35.61) 14.29 (± 26.30) 
Diabetes mellitus 
Yes (n = 6) 26.07 (± 29.75) 16.57 (± 21.64 )            0.056 0.092 0.592 
No (n=14) 5.5 (±13.47) 0 
Hypertension 
Yes (n = 15) 22.13 (± 29.98) 13.27 (± 21.05)        0.063 0.518 0.775 
No  (n = 5) 13.2 (± 18.07) 6.6 (± 14.76) 
Constipation symptoms scale 
Lymphadenectomy performed 
Yes (n = 11) 30.09 (± 27.68)   12 (± 16.65)  0.011 0.867 0.945 
No  (n = 7) 28.57 (± 40.55) 9.57 (± 25.32) 
Diabetes mellitus 
Yes (n = 6) 27.67 (± 25.15)    5.5 (± 13.47)        0.007 0.599 0.662 
No (n = 14) 30.79 (± 33.23) 14.21 (± 21.51) 
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Hypertension 
Yes (n = 15) 30.93 (± 32.03) 13.27 (± 21.05) 0.011 0.644 0.864 
No  (n = 5) 26.6 (± 27.97) 6.6 (± 14.76) 
Diarrhoea symptom scale 
Lymphadenectomy performed 
Yes (n = 11) 18.09 (± 22.90)     51.55 (± 34.64)       < 0.001 0.792 0.768 
No  (n = 7) 18.86 (± 17.64) 57.29 (± 41.82) 
Diabetes mellitus 
Yes (n = 6) 11 (± 17.04) 50 (± 54.77)         < 0.001 0.455 0.923 
No (n = 14) 18.93 (± 21.50) 59.64 (± 26.86) 
Hypertension 
Yes (n = 15) 15.47 (± 21.29)    55.6 (± 37.17)             < 0.001 0.722 0.989 
No  (n = 5) 19.8 (± 18.07) 60.2 (± 36.56) 
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Table 7. EORTC QLQ-EN24 — differences between groups 
 
 
 
EORTC QLQ-EN24  scales 
Questionnaire timepoints P value  
 
Start of  
treatment 
Mean (± SD) 
 
End of 
treatment 
Mean (± SD) 
Changes 
over time 
Difference 
between 
groups 
Difference 
between 
groups over 
time 
Gastrointestinal symptoms scores 
Lymphadenectomy performed 
Yes (n = 11) 14.45 (± 15.19) 23.55 (± 21.23) 0.006 0.443 0.394 
No  (n = 7) 18.14 (± 19.84) 34.29 (± 27.52) 
Diabetes mellitus 
Yes (n = 6) 14.5 (± 23.61) 27.33 (± 33.68) 0.006 0.934 0.903 
No (n = 14) 14.21 (± 13.57) 26.07 (± 17.90) 
Hypertension 
Yes (n = 15) 13.67 (± 16.40) 24.2 (± 22.07) 0.003 0.555 0.440 
No  (n = 5) 16.2 (± 18.67) 33.2 (± 26.10) 
Urological symptoms score 
Lymphadenectomy performed 
Yes (n = 11) 29.64 (± 24.82) 37.91 (± 32) 0.143 0.851 0.736 
No  (n = 7) 25 (± 18.06) 38 (± 35.70) 
Diabetes mellitus 
Yes (n = 6) 20.83 (± 21.67) 36 (± 35.30) 0.085 0.813 0.638 
No (n = 14) 26.86 (± 23.37) 35.71 (± 31.17) 
Hypertension 
Yes (n = 15) 26.13 (± 23.53) 37.73 (± 34.13) 0.175 0.638 0.811 
No  (n = 5) 21.8 (± 21.07) 30 (± 24.12) 
Pain in back and pelvis score 
Lymphadenectomy performed 
Yes (n = 11) 21.09 (± 22.45) 39.27 (± 29.23) 0.086 0.952 0.297 
No  (n = 7) 28.43 (± 23.05) 33.14 (± 19.34) 
Diabetes mellitus 
Yes (n = 6) 33.17 (± 21.19) 27.67 (± 25.15) 0.238 0.846 0.040 
No (n = 14) 18.93 (± 21.50) 37.93 (± 25.78) 
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Hypertension 
Yes (n = 15) 19.8 (± 16.73) 35.4 (± 26.70) 0.240 0.598 0.228 
No  (n = 5) 33.4 (± 33.50) 33.2 (± 23.69) 
 
 
